<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bactericidal/permeability-increasing protein (BPI), a constituent of primary neutrophil granules, is a potent natural antibiotic and an antineutrophil cytoplasm antibody (<z:chebi fb="0" ids="34507">ANCA</z:chebi>) antigen in cases of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> in which the target antigen is neither myeloperoxidase (MPO) nor proteinase-3 (PR3) </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To investigate BPI as a possible target antigen for <z:chebi fb="0" ids="34507">ANCAs</z:chebi> in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:chebi fb="0" ids="34507">ANCAs</z:chebi> were detected by routine immunofluorescence (IIF) and solid phase enzyme linked immunosorbent assay (ELISA) performed for antibodies to the purified neutrophil granule proteins; MPO, PR3, cathepsin-G, lactoferrin, and BPI in serum samples from 88 patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (36 with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, 52 with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty patients with <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0014335" disease_type="Disease or Syndrome" abbrv="">enteritis</z:e> acted as controls </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Significantly more patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> were <z:chebi fb="0" ids="34507">ANCA</z:chebi> positive by IIF (60%) than patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (28%) or <z:e sem="disease" ids="C0021342" disease_type="Disease or Syndrome" abbrv="">infectious enteritis</z:e> (23%) (p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>IgG anti-BPI antibodies were present in 29% of patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, 14% of patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, and 23% of patients with <z:e sem="disease" ids="C0021342" disease_type="Disease or Syndrome" abbrv="">infectious enteritis</z:e>, occurring in 44% of those patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> who were <z:chebi fb="0" ids="34507">ANCA</z:chebi> positive by IIF </plain></SENT>
<SENT sid="6" pm="."><plain>Antibodies to other <z:chebi fb="0" ids="34507">ANCA</z:chebi> antigens were rare </plain></SENT>
<SENT sid="7" pm="."><plain>The presence of <z:chebi fb="0" ids="34507">ANCAs</z:chebi> was not related to either disease activity or extent; presence of anti-BPI antibodies was significantly related to both a lower serum albumin concentration (p = 0.001) and a higher erythrocyte sedimentation rate (p = 0.02) in patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, and to colonic involvement in patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (p = 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: BPI is a significant minority target antigen for <z:chebi fb="0" ids="34507">ANCAs</z:chebi> in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> that seems related to colonic <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and disease activity in <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Anti-BPI antibodies occur in <z:e sem="disease" ids="C0021342" disease_type="Disease or Syndrome" abbrv="">infectious enteritis</z:e> </plain></SENT>
</text></document>